Retracted: Magnesium supplementation affects metabolic status and pregnancy outcomes in gestational diabetes: a randomized, double-blind, placebo-controlled trial.
Study Goal
The researchers aimed to assess the effects of magnesium supplementation on metabolic status and pregnancy outcomes in magnesium-deficient pregnant women with gestational diabetes (GDM).
Results Summary
Magnesium supplementation significantly improved metabolic markers (e.g., fasting glucose, insulin resistance) and pregnancy outcomes (e.g., reduced newborn hyperbilirubinemia and hospitalization rates) compared to placebo.
Population
Magnesium-deficient pregnant women with gestational diabetes (GDM).
Effective Dosage
250 mg magnesium oxide daily.
Duration
6 weeks.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
magnesium supplementation | increase | serum magnesium concentration | women with GDM | +0.06 ± 0.3 vs. -0.1 ± 0.3 mg/dL | greater change in | #1 |
magnesium supplementation | decrease | fasting plasma glucose | women with GDM | -9.7 ± 10.1 vs. +1.8 ± 8.1 mg/dL | changes in | #2 |
magnesium supplementation | decrease | serum insulin concentration | women with GDM | -2.1 ± 6.5 vs. +5.7 ± 10.7 μIU/mL | changes in | #3 |
magnesium supplementation | decrease | homeostasis model of assessment-estimated insulin resistance | women with GDM | -0.5 ± 1.3 vs. +1.4 ± 2.3 | changes in | #4 |
magnesium supplementation | decrease | homeostasis model of assessment-estimated β-cell function | women with GDM | -4.0 ± 28.7 vs. +22.0 ± 43.8 | changes in | #5 |
magnesium supplementation | increase | quantitative insulin sensitivity check index | women with GDM | +0.004 ± 0.021 vs. -0.012 ± 0.015 | changes in | #6 |
magnesium supplementation | increase | serum triglycerides | women with GDM | +2.1 ± 63.0 vs. +38.9 ± 37.5 mg/dL | changes in | #7 |
magnesium supplementation | decrease | high sensitivity C-reactive protein | women with GDM | -432.8 ± 2521.0 vs. +783.2 ± 2470.1 ng/mL | changes in | #8 |
magnesium supplementation | decrease | plasma malondialdehyde concentrations | women with GDM | -0.5 ± 1.6 vs. +0.3 ± 1.2 μmol/L | changes in | #9 |
magnesium supplementation | decrease | newborn hyperbilirubinemia | women with GDM | 8.8% vs. 29.4% | resulted in a lower incidence of | #10 |
magnesium supplementation | decrease | newborn hospitalization | women with GDM | 5.9% vs. 26.5% | resulted in a lower incidence of | #11 |
BACKGROUND: To our knowledge, prior research has not examined the effects of magnesium supplementation on metabolic status and pregnancy outcomes in maternal-child dyads affected by gestational diabetes (GDM). OBJECTIVE: This study was designed to assess the effects of magnesium supplementation on metabolic status and pregnancy outcomes in magnesium-deficient pregnant women with GDM. DESIGN: A randomized, double-blind, placebo-controlled clinical trial was performed in 70 women with GDM. Patients were randomly assigned to receive either 250 mg magnesium oxide (n = 35) or a placebo (n = 35) for 6 wk. Fasting blood samples were taken at baseline and after a 6-wk intervention. RESULTS: The change in serum magnesium concentration was greater in women consuming magnesium than in the placebo group (+0.06 ± 0.3 vs. -0.1 ± 0.3 mg/dL, P = 0.02). However, after controlling for baseline magnesium concentrations, the changes in serum magnesium concentrations were not significantly different between the groups. Changes in fasting plasma glucose (-9.7 ± 10.1 vs. +1.8 ± 8.1 mg/dL, P < 0.001), serum insulin concentration (-2.1 ± 6.5 vs. +5.7 ± 10.7 μIU/mL, P = 0.001), homeostasis model of assessment-estimated insulin resistance (-0.5 ± 1.3 vs. +1.4 ± 2.3, P < 0.001), homeostasis model of assessment-estimated β-cell function (-4.0 ± 28.7 vs. +22.0 ± 43.8, P = 0.006), and the quantitative insulin sensitivity check index (+0.004 ± 0.021 vs. -0.012 ± 0.015, P = 0.005) in supplemented women were significantly different from those in women in the placebo group. Changes in serum triglycerides (+2.1 ± 63.0 vs. +38.9 ± 37.5 mg/dL, P = 0.005), high sensitivity C-reactive protein (-432.8 ± 2521.0 vs. +783.2 ± 2470.1 ng/mL, P = 0.03), and plasma malondialdehyde concentrations (-0.5 ± 1.6 vs. +0.3 ± 1.2 μmol/L, P = 0.01) were significantly different between the supplemented women and placebo group. Magnesium supplementation resulted in a lower incidence of newborn hyperbilirubinemia (8.8% vs. 29.4%, P = 0.03) and newborn hospitalization (5.9% vs. 26.5%, P = 0.02). CONCLUSION: Magnesium supplementation among women with GDM had beneficial effects on metabolic status and pregnancy outcomes. This trial was registered at www.irct.ir as IRCT201503055623N39.